Cresset Asset Management LLC Invests $233,000 in Progyny, Inc. $PGNY

Cresset Asset Management LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,432 shares of the company’s stock, valued at approximately $233,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. New York State Teachers Retirement System boosted its position in Progyny by 0.7% during the first quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock valued at $1,635,000 after purchasing an additional 500 shares during the last quarter. Voya Investment Management LLC grew its stake in shares of Progyny by 1.4% in the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company’s stock valued at $893,000 after buying an additional 701 shares in the last quarter. Polen Capital Management LLC increased its holdings in Progyny by 0.3% during the first quarter. Polen Capital Management LLC now owns 261,506 shares of the company’s stock worth $5,842,000 after buying an additional 798 shares during the last quarter. Invesco Ltd. increased its holdings in Progyny by 0.4% during the first quarter. Invesco Ltd. now owns 275,936 shares of the company’s stock worth $6,164,000 after buying an additional 1,117 shares during the last quarter. Finally, First Trust Advisors LP raised its position in Progyny by 13.1% during the fourth quarter. First Trust Advisors LP now owns 24,105 shares of the company’s stock worth $416,000 after acquiring an additional 2,794 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Down 2.2%

Progyny stock opened at $22.64 on Wednesday. The company’s 50-day moving average price is $22.62 and its two-hundred day moving average price is $22.18. The stock has a market cap of $1.95 billion, a P/E ratio of 38.37, a P/E/G ratio of 1.89 and a beta of 1.32. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $26.76.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). The firm had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 EPS. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Equities analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on PGNY. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective (up previously from $26.00) on shares of Progyny in a research report on Friday, August 8th. Truist Financial raised their target price on shares of Progyny from $24.00 to $27.00 and gave the company a “hold” rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. lifted their price target on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Finally, Leerink Partners raised Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price objective for the company in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.30.

Insiders Place Their Bets

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the transaction, the director owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total value of $59,037.25. Following the sale, the director directly owned 14,112 shares of the company’s stock, valued at $311,451.84. This represents a 15.93% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.40% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.